Document ID: chunk:federal_register_of_legislation:F2024C00843:reg:15ga
Version: federal_register_of_legislation:F2024C00843
Segment Type: reg
Provision Reference: reg 15GA
Character Range: 55676–57164

15GA  Responsibilities while restrictive practice being used
  If an approved provider uses a restrictive practice in relation to a care recipient, the approved provider must ensure that while the restrictive practice is being used:
 (a) the care recipient is monitored for the following:
 (i) signs of distress or harm;
 (ii) side effects and adverse events;
 (iii) changes in mood or behaviour;
 (iv) changes in well‑being, including the care recipient's ability to engage in activities that enhance quality of life and are meaningful and pleasurable;
 (v) changes in the care recipient's ability to maintain independent function (to the extent possible);
 (vi) changes in the care recipient's ability to engage in activities of daily living (to the extent possible); and
 (b) the necessity for the use of the restrictive practice is regularly monitored, reviewed and documented; and
 (c) the effectiveness of the use of the restrictive practice, and the effect of changes in the use of the restrictive practice, are monitored; and
 (d) to the extent possible, changes are made to the care recipient's environment to reduce or remove the need for the use of the restrictive practice; and
 (e) if the restrictive practice is chemical restraint—information about the effects and use of the chemical restraint is provided to the medical practitioner or nurse practitioner who prescribed the medication for the purpose of using the chemical restraint as mentioned in paragraph 15FC(1)(a).